-Business Standard Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation. A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner...
More »SEARCH RESULT
Doesn't India Already Have an IPR Policy? -Sunil Mani
-Economic and Political Weekly The National Democratic Alliance government has constituted the IPR Think Tank which, among other things, is to draft the National Intellectual Property Rights Policy. India may not have a policy per se but it has a strong legislation on IPRs, a functioning patents office and mechanisms to grant patents as well as protect consumer interests. The Think Tank has other issues it needs to address, but is...
More »Made for Big Pharma -Paranjoy Guha Thakurta
-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...
More »Centre sits on royalty slabs for bio resources, loses Rs 25,000 cr a year -Jay Mazoomdaar
-The Indian Express It took the National Biodiversity Authority (NBA) six years, 18 drafts and a prod from the National Green Tribunal (NGT) to finalise the Guidelines for Access and Benefit Sharing (ABS) this August. Three months on, it is yet to notify the rules that would allow it to collect from domestic and foreign companies 0.1-1 per cent of their ex-factory gross sales of products using biological resources and traditional...
More »A reality check on intellectual property concerns -Moushami Joshi and Srividhya Ragavan
-The Hindu The Working Group on Intellectual Property can serve as a platform where real time solutions to meet India's need for low-cost medicines can be addressed After what seemed like a historic trip for Prime Minister Narendra Modi, which held out the promise of reshaping India-U.S. relations positively, the initiation of the Out-of-Cycle Review (OCR) by the United States Trade Representative (USTR) has brought a sobering reality check as to what...
More »